Please login to the form below

Not currently logged in


This page shows the latest Immunology news and features for those working in and with pharma, biotech and healthcare.

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

Boehringer builds in immuno-oncology with €1.1bn-plus OSE deal

The company that that the OSE collaboration “strengthens a core pillar of [our] cancer immunology and immune modulation strategy focusing on novel approaches to treat cancer”. ... of cancer immunology and immune modulation research.

Latest news

More from news
Approximately 7 fully matching, plus 165 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Back in June 2015 Celgene and Juno announced a ten-year collaboration to combine their respective immunology expertise to develop new immunotherapies for cancer and autoimmune diseases based on T cell

  • The good, the bad and the ugly The good, the bad and the ugly

    selling drug until its patent expiry in the US in 2023, ”says Alexandra Annis, senior analyst, immunology, GlobalData. ... The immunology market has seen setbacks too, with sales at both Pfizer (-3.6%) and Amgen (-10.8%) notably declining.

  • Digital disruption Digital disruption

    Clearly these aren’t isolated examples. Pfizer has teamed up with IBM to accelerate its search for immunology treatments, hoping to identify new drug treatments.

  • Taking a lean and careful approach Taking a lean and careful approach

    with a promising pipeline across multiple programmes for oncology and immunology.

  • Deal Watch November 2016 Deal Watch November 2016

    malignancies. As with PD-1 and other checkpoints, TAMs regulate the immune response to cancer and therefore TAMs have broad application and potential across immuno-oncology and immunology.

More from intelligence
Approximately 3 fully matching, plus 30 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 65 partially matching documents found.

Latest from PMHub

  • Perspective on biotech

    Perspective on biotech. In this supplementary issue of Perspective, we reveal the emerging technologies taking the biotech world by storm and ask if the definition of a biotech organisation needs updating. Biotech companies operate in highly complex

  • Living with Crohn's disease: a patient perspective

    Living with Crohn's disease: a patient perspective. Account Executive Victoria Morton explores what it’ s like to live with Crohn’ s disease as a young person, and investigates what’ s being done to tackle the gaps in treatment options for

  • Creativity in a complex landscape: a pharma perspective

    Mohamed: We have multiple therapy areas in immunology – dermatology, gastroenterology, and rheumatology – and I primarily work with gastroenterology. ... When we develop campaigns at an EMEA level for immunology, we separate our markets into ‘

  • Focus on immunotherapies: special magazine from Blue Latitude Health

    The immunotherapy special issue covers:. Immunology in oncology as a therapy area – what it is, how it works, and where it’ s heading from a medical and commercial point of view.

  • Pegasus shortlisted for four PM Society Digital Media Awards 2016

    Pegasus’ s pharmaceutical and life sciences clients currently include Boehringer Ingelheim, CSL Behring, Daiichi Sankyo, Fittleworth, GlaxoSmithKline, MSD Immunology, Novartis, Novo Nordisk Global, Nutricia Advanced Medical Nutrition, Pfizer,

More from PMHub
Approximately 3 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...